Sandoz targets 100 biosimilars by 2040, backs ambition with $300 million Slovenia plant

Swiss drugmaker Sandoz used its Capital Markets Day in London to unveil Bio100, a plan to expand its biosimilars portfolio to more than 100 products by 2040, up from 13 today, alongside a new $300 million investment in manufacturing in Slovenia.

Under Bio100, Sandoz is targeting biosimilar coverage of around 80% of the value tied to medicines losing exclusivity from 2035, roughly double today's approximately 50%. The company introduced a new mid-term outlook for 2025 to 2030, targeting mid-to-high single-digit annual net sales growth at constant currencies and a core earnings before interest, taxes, depreciation and amortization (EBITDA) margin of 25% to 27% by 2030, including the impact of GLP-1 medicines.